Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Dec
20
Today In Oncology
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
Data Published on Incidence of Immune Checkpoint Inhibitor-Associated ITP
Lymphocyte Kinetics After CAR T Infusion Predict Survival Outcomes in Non-Hodgkin Lymphoma
CD123-Targeting ADC Shows Activity in AML and BPDCN
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo